Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Rhea-AI Summary

Renovaro Inc. (NASDAQ: RENB) has secured an expedited trial in 2025 for its lawsuit against Predictive Oncology (NASDAQ: POAI) regarding a disputed merger agreement. The lawsuit, filed on May 9, 2025, in Delaware Court of Chancery, seeks to enforce a binding merger agreement signed on January 1, 2025. Following the agreement's public disclosure, POAI's stock price increased by over 50%.

Renovaro alleges that Predictive Oncology breached the agreement by conducting a $545,000 public offering on February 19, 2025, violating contractual restrictions, and attempting to unilaterally terminate the agreement on April 3, 2025. The lawsuit seeks specific performance, injunctive relief, and damages for the alleged breaches.

Positive

• Expedited trial schedule could lead to faster resolution of the merger dispute
• Original merger agreement caused POAI stock to rise over 50%, indicating market approval

Negative

• Legal uncertainty surrounding the merger's completion
• Potential costs and resources devoted to litigation
• Breach of exclusivity agreement by POAI through $545,000 public offering
• Risk of merger falling through due to POAI's attempted unilateral termination

News Market Reaction – RENB

+15.28%

1 alert

+15.28% News Effect

On the day this news was published, RENB gained 15.28%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025.

According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following the public disclosure of the agreement in a Form 8-K filed by POAI on January 6, 2025, POAI’s stock price rose by more than 50%.

Renovaro alleges that Predictive Oncology breached the agreement’s exclusivity and good faith negotiation provisions by conducting a public offering of $545,000 in securities on February 19, 2025—despite contractual restrictions—and later attempting to terminate the agreement unilaterally on April 3, 2025, without engaging meaningfully in the negotiation of a definitive merger agreement.

“This transaction was intended to create strategic and shareholder value for both companies. Unfortunately, Predictive Oncology has disregarded its contractual commitments,” said a Renovaro spokesperson. “We are pursuing legal remedies to enforce our rights and protect our shareholders’ interests.”

The litigation seeks specific performance, injunctive relief, and damages for the alleged breaches. The case is pending in the Delaware Court of Chancery under Case No. 2025-0509.

About Renovaro Inc.

Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit www.renovarogroup.com.

Forward-Looking Statements

This release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations

Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us

For media inquiries, please contact:

karen@renovarocube.com

FAQ

What is the lawsuit between Renovaro (RENB) and Predictive Oncology about?

Renovaro filed a lawsuit on May 9, 2025, seeking to enforce a binding merger agreement signed with Predictive Oncology on January 1, 2025, after POAI allegedly breached the agreement's terms and attempted to terminate it unilaterally.

When did Predictive Oncology attempt to terminate the merger agreement with Renovaro?

Predictive Oncology attempted to unilaterally terminate the merger agreement on April 3, 2025, without engaging meaningfully in definitive merger agreement negotiations.

How did POAI's stock price react to the merger announcement with Renovaro?

Following the public disclosure of the merger agreement on January 6, 2025, POAI's stock price rose by more than 50%.

What specific breaches does Renovaro allege against Predictive Oncology?

Renovaro alleges that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions by conducting a $545,000 public offering on February 19, 2025, and later attempting to terminate the agreement unilaterally.

What legal remedies is Renovaro seeking in its lawsuit against POAI?

Renovaro is seeking specific performance, injunctive relief, and damages for the alleged breaches in the Delaware Court of Chancery (Case No. 2025-0509).